Ajanta Pharma has entered into an agreement with Canada-based Prollenium Medical Technologies to market its dermal filler Revanesse in India.According to an official release issued by Ajanta Pharma to the BSE today, under the agreement, the company will have exclusive marketing rights (EMR) for Revanesse, which it hopes will further boost its corporate equity amongst cosmetologists and dermatologists."Launch of this product is of great significance for Ajanta as we continue to build our strengths in dermatology segment...The deal will be perfect synergy as Prollenium technologies has over 25 years of experience in the medical aesthetic industry, and we are currently developing cutting edge and time-tested products for the aesthetic market" Yogesh M Agrawal, executive director, Ajanta Pharma, said.The country's dermatology market is valued at approximately Rs 1,300 crore as per ORO-IMS and lifestyle cosmeceutical products like dermal fillers and anti-ageing products are fast gaining popularity, the release said.
